Cerebral Hyperperfusion Syndrome after Revascularization Surgery in Patients with Moyamoya Disease: Systematic Review and Meta-analysis.
Cerebral hyperperfusion syndrome (CHS) following bypass surgery is known as a complication of moyamoya disease (MMD). However, the incidence of CHS has not been accurately reported, and there is no consensus on related risk factors. To evaluate the incidence and characteristics of CHS in patients with MMD after revascularization surgery via meta-analysis. Relevant cohort studies were retrieved through a literature search in PubMed, Embase and Ovid until December 1, 2018. Eligible studies were identified per search criteria. A systematic review and meta-analysis were used to assess the CHS total incidence, incidence in pediatric MMD patients and adult MMD patients, incidence for direct and combined bypass surgery, progress rate, proportion of each symptom (included transient neurological deficits (TNDs), haemorrhage and seizure). A total of 27 cohort studies with 2,225 patients were included in this meta-analysis. The weighted proportions per random-effects model were 16.5% (11.3% to 22.3%) for the CHS total incidence, 3.8% (0.3% to 9.6%) for pediatric MMD patients, and 19.9% (11.7% to 29.4%) for adult MMD patients, 15.4% (5.4% to 28.8%) for direct bypass surgery and 15.2% (8.4% to 23.2%) for combined bypass surgery. Progress rate was 39.5% (28.7% to 50.8%). The most common CHS-related symptoms were TNDs 70.2% (56.3% to 82.7%), followed by haemorrhage 15.0% (5.5% to 26.9%) and seizure 5.3% (0.6% to 12.9%). CHS is a common complication after revascularization surgery in MMD. It is more frequently seen in adult patients. The most common CHS-related symptoms were TNDs, followed by haemorrhage and seizure.